http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9011867-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d51a3bbd3fa1ddc931c4f18ecd02cb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96ba7fcf4dbb9188f9005a200e9579c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_63ec18cc758d36256329d09f7f52ba92 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-804 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0784 |
| filingDate | 2010-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acf49cc9945dcca5dd79eaf1298487ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b70689c6e21e43053a9570947a709857 |
| publicationDate | 2015-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9011867-B2 |
| titleOfInvention | Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (MGUS) or of smoldering multiple myeloma (SMM) |
| abstract | The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). Moreover, the present invention relates to the use of an activated T-cell specifically recognizing the peptide of the present invention or an antigen presenting cell which specifically presents a peptide epitope of the present invention for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). The present invention also relates to a method for the ex vivo manufacture of an activated T-cell of the present invention comprising the steps of: a) obtaining T-cells from a sample of a subject suffering from MGUS or SMM, b) contacting said T-cells with a peptide of the present invention, and c) collecting the activated T-cells. The present invention relates further to a method for the ex vivo manufacture of an antigen presenting cell of the present invention comprising the steps of: a) obtaining immature antigen presenting cells from a sample of a subject suffering from MGUS or SMM, b) contacting said immature antigen presenting cells with a peptide of the present invention, and c) collecting the mature antigen presenting cells. |
| priorityDate | 2009-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.